Compare CAC & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | CERT |
|---|---|---|
| Founded | 1875 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.1M | 860.9M |
| IPO Year | 1996 | 2020 |
| Metric | CAC | CERT |
|---|---|---|
| Price | $49.52 | $5.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $47.00 | $11.67 |
| AVG Volume (30 Days) | 77.7K | ★ 3.2M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | 6.08 | ★ 87.50 |
| EPS | ★ 1.29 | N/A |
| Revenue | $41,739,000.00 | ★ $418,838,000.00 |
| Revenue This Year | $19.15 | $4.18 |
| Revenue Next Year | $6.05 | $5.39 |
| P/E Ratio | $38.29 | ★ N/A |
| Revenue Growth | ★ 16.96 | 8.75 |
| 52 Week Low | $35.00 | $4.45 |
| 52 Week High | $53.71 | $13.88 |
| Indicator | CAC | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 44.91 |
| Support Level | $47.12 | $5.19 |
| Resistance Level | $51.57 | $6.47 |
| Average True Range (ATR) | 1.10 | 0.35 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 78.19 | 39.65 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.